Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Latrepirdine: Molecular mechanisms underlying potential therapeutic roles in Alzheimer’s and other neurodegenerative diseases

    195423_103198_78692.pdf (416.3Kb)
    Access Status
    Open access
    Authors
    Bharadwaj, P.
    Bates, K.
    Porter, T.
    Teimouri, E.
    Perry, G.
    Steele, J.
    Gandy, S.
    Groth, David
    Martins, R.
    Verdile, G.
    Date
    2013
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Bharadwaj, P.R. and Bates, K.A. and Porter, T. and Teimouri, E. and Perry, G. and Steele, J.W. and Gandy, S. and Groth, D. and Martins, R.N. and Verdile, Giuseppe. 2013. Latrepirdine: Molecular mechanisms underlying potential therapeutic roles in Alzheimer’s and other neurodegenerative diseases. Translational Psychiatry. 3 (e332): pp. 1-9.
    Source Title
    Translational Psychiatry
    DOI
    10.1038/tp.2013.97
    ISSN
    2158-3188
    Remarks

    This article is published under the Open Access publishing model and distributed under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by-nc-sa/3.0/. Please refer to the licence to obtain terms for any further reuse or distribution of this work.

    URI
    http://hdl.handle.net/20.500.11937/26082
    Collection
    • Curtin Research Publications
    Abstract

    Latrepirdine (DimebonTM) was originally marketed as a non-selective antihistamine in Russia. It was repurposed as an effective treatment for patients suffering from Alzheimer’s disease (AD) and Huntington’s disease (HD) following preliminary reports showing its neuroprotective functions and ability to enhance cognition in AD and HD models. However, latrepirdine failed to show efficacy in phase III trials in AD and HD patients following encouraging phase II trials. The failure of latrepirdine in the clinical trials has highlighted the importance of understanding the precise mechanism underlying its cognitive benefits in neurodegenerative diseases before clinical evaluation. Latrepirdine has shown to affect a number of cellular functions including multireceptor activity, mitochondrial function, calcium influx and intracellular catabolic pathways; however, it is unclear how these properties contribute to its clinical benefits. Here, we review the studies investigating latrepirdine in cellular and animal models to provide a complete evaluation of its mechanisms of action in the central nervous system. In addition, we review recent studies that demonstrate neuroprotective functions for latrepirdine-related class of molecules including the β-carbolines and aminopropyl carbazoles in AD, Parkinson’s disease and amyotrophic lateral sclerosis models. Assessment of their neuroprotective effects and underlying biological functions presents obvious value for developing structural analogues of latrepirdine for dementia treatment.

    Related items

    Showing items related by title, author, creator and subject.

    • The Effects of Latrepirdine on Amyloid-ß Aggregation and Toxicity
      Porter, T.; Bharadwaj, P.; Groth, David; Paxman, A.; Laws, S.; Martins, R.; Verdile, Giuseppe (2016)
      © 2016 - IOS Press and the authors. All rights reserved. Latrepirdine (DimebonTM) has been demonstrated to be a neuroprotective and cognition improving agent in neurodegenerative diseases that feature protein aggregation ...
    • Latrepirdine (Dimebon™) enhances autophagy and reduces intracellular GFP-A42 levels in yeast
      Bharadwaj, P.; Verdile, Giuseppe; Barr, R.; Gupta, V.; Steele, J.; Lachenmayer, M.; Yue, Z.; Ehrlich, M.; Petsko, G.; Ju, S.; Ringe, D.; Sankovich, S.; Caine, J.; Macreadie, I.; Gandy, S.; Martins, R. (2012)
      Latrepirdine (Dimebon™), an anti-histamine, has shown some benefits in trials of neurodegenerative diseases characterized by accumulation of aggregated or misfolded protein such as Alzheimer’s disease (AD) and has been ...
    • A review of lexical retrieval intervention in primary progressive aphasia and Alzheimer’s disease: mechanisms of change, generalisation, and cognition
      Beales, A.; Whitworth, Anne; Cartwright, J. (2018)
      © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group. Background: While significant benefits of lexical retrieval intervention are evident within the primary progressive aphasia (PPA) and Alzheimer’s ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.